[Skip to Navigation]
January 1972

Graves' Disease in the Male: A Review of 241 Cases Treated With an Individually Calculated Dose of Sodium Iodide I 131

Author Affiliations

Los Angeles; Buffalo, NY

From Nuclear Medicine Service, Wadsworth Hospital, Veterans Administration, Los Angeles, and Department of Medicine, UCLA School of Medicine (Dr. Blahd); and Nuclear Medicine Service, Veterans Administration Hospital, and departments of medicine and biophysics, State University of New York, Buffalo (Dr. Hays).

Arch Intern Med. 1972;129(1):33-40. doi:10.1001/archinte.1972.00320010037002

This report encompasses a 20-year study of 241 male patients with Graves' disease. All patients received a therapeutic dose of sodium iodide I 131 calculated from the 24-hour thyroid uptake, the effective half-life of the retained 131I tracer dose, and the gland weight. The gland weight was determined by an empirical weight formula from the thyroid scintigram. Forty-five percent of the total patient group and 74% of the Negro patients required multiple doses. Patients who required multiple doses had more severe laboratory abnormalities and lost more weight. These patients also became hypothyroid later and ultimately had a higher incidence of hypothyroidism than patients who received single doses. The mean incidence of hypothyroidism for the entire series was 27.8%. The actual number of millicuries of 131I required to deliver the therapeutic dose had little or no relation to the ultimate therapeutic effect.